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Abstract Multifocal motor neuropathy (MMN) is a rare
immune-mediated disorder and is characterized by male
predominance, the presence of serum anti-GM1 IgM anti-
bodies in up to half of all patients, responsiveness to
intravenous immunoglobulins (IVIg) and an increased
frequency of HLA type HLA-DRB1*15. The aim of this
study was to assess whether the frequency of autoimmune
diseases (AID) is increased in patients with MMN and their
ﬁrst-degree family members, since this would indicate that
MMN shares pathogenic mechanisms with other AID. We
conducted a case–control study using questionnaires to
evaluate the prevalence of AID in MMN and controls, and
their ﬁrst-degree relatives. Questionnaires from 81 MMN
patients (417 ﬁrst-degree relatives) and 438 controls (2,377
ﬁrst-degree relatives) were analyzed. Overall prevalence of
AID was higher in MMN patients (11%) than in controls
(5%) (OR 2.4, 95% CI 1.1–5.5, p = 0.037). Type 1 dia-
betes, Hashimoto’s thyroid disease, and celiac disease were
signiﬁcantly more prevalent in family members of patients
than controls. The presence of an additional AID was not
associated with age at MMN onset, disease duration, titer
of serum anti-GM1 IgM antibodies or HLA type HLA-
DRB1*15. The higher frequency of AID in patients with
MMN indicates a common autoimmune diathesis.
Keywords Autoimmune diseases  Multifocal motor
neuropathy
Introduction
Multifocal motor neuropathy (MMN) is an immune-medi-
ated chronic asymmetrical motor neuropathy [11, 12]. More
than 90% of patients with MMN respond favourably to
treatment with intravenous immunoglobulins (IVIg) and
sera of up to 50% of patients with MMN contain IgM
antibodies against the ganglioside GM1 [6], which is highly
expressed in motor nerves [19]. MMN aetiology has not
been fully elucidated. Anti-GM1 IgM antibodies probably
play a pathogenic role in MMN [5]. We recently reported an
association of MMN with HLA DRB1*15, which might
indicate that MMN shares pathogenetic pathways with other
autoimmune diseases (AID) [15]. AID tend to cluster in
relatives of patients with neurological AID such as multiple
sclerosis (MS), the Lambert-Eaton myasthenic syndrome
(LEMS), and myasthenia gravis (MG) [4, 8, 20]. To assess
whether patients with MMN share a common autoimmune
diathesis we conducted a case–control study using ques-
tionnaires to compare frequencies of AID in controls and
MMN patients, and their ﬁrst-degree relatives.
Materials and methods
The cases were patients with MMN who participated in a
national cross-sectional study on MMN conducted in the
Netherlands from January until December 2007 [6].
Inclusion criteria were diagnoses of deﬁnite, probable or
possible MMN according to criteria published previously
[17]. All MMN patients were approached by telephone and
asked to complete a postal questionnaire. Non-responders
were again contacted by telephone after 3 months.
Six hundred and ﬁfty population-based controls from a
control database were approached by mail and asked to
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who returned incomplete questionnaires were contacted by
telephone in order to complete the data.
The questionnaire was designed to document gender,
date of birth and family history regarding ﬁrst-degree rel-
atives (parents, siblings), and the presence of the 18 most
prevalent AID in the Netherlands according to the data
collected by the Dutch Central Bureau for Statistics.
For each speciﬁc disease a description in layman’s terms
was provided and subjects were asked whether they or their
parents or siblings (living and deceased) had any of the
AID listed. Additional questions were asked if patients or
controls reported any of the following three AID: (1) for
type 1 diabetes, age at disease onset and use of insulin were
used to differentiate type 1 from type 2 diabetes [1]. (2)
Since previous studies showed that the presence of rheu-
matoid arthritis (RA) tended to be over-reported in a
comparable study design [4], subjects were asked if the
affected individuals were being treated by a rheumatologist
to differentiate between actual RA and other, non-AID with
affected joints such as osteoarthritis. (3) To differentiate
between pernicious anaemia and other forms of anaemia,
subjects were asked if the affected individuals were or had
been treated with vitamin B12 injections.
Two diseases other than AID, myocardial infarction and
asthma, were included in the questionnaire to control for
reporting bias. These diseases have a high prevalence in the
general population and no suspected relation with MMN or
AID in general.
Both patients and controls who reported the presence of
AID were contacted by phone and by a medical doctor to
ensure the validity of the diagnosis.
The Medical Ethical Committee of the University
Medical Center (UMC) Utrecht approved the study and the
study was therefore performed in accordance with the
ethical standards laid down in the 1964 Declaration of
Helsinki. All participants gave written informed consent
prior to the study.
Prevalence of AID in patients and controls, as well as in
families, was analysed with logistic regression analysis and
adjusted for age. Differences between patients with and
patientswithoutanAIDweretestedusingtheMann–Whitney
U test and the v
2 or Fisher’s exact test when appropriate.
Results
Eighty-eight MMN patients [6] and 600 potential controls
were asked to participate in this study and were approached
by mail. Questionnaires of 81 MMN patients (response rate
92%) and 438 (response rate 73%) controls were returned.
In total, 2,794 relatives of 519 index cases and controls
were included in this survey.
Characteristics of MMN patients and controls
Characteristics of MMN patients and controls are sum-
marized in Table 1. The median duration of MMN at
inclusion was 14 years (range 1–46 years) and the median
age at onset of disease was 41 years (range 22–66 years).
The control group (n = 438) included 108 women (25%), a
percentage comparable to the patient group, but the median
age at inclusion was higher in controls (p = 0.004). We
adjusted for the difference in age in the statistical analysis.
AID in MMN patients and controls
Table 2 summarizes the prevalence of speciﬁc AID in
MMN patients and controls. Nine MMN patients (11%)
had one or more of the listed AID. One MMN patient
(1.2%) had two of the listed AID: Crohn’s disease and
ankylosing spondylitis; the other eight MMN patients
(9.9%) had one of the listed AID. The presence of AID was
not associated with patient characteristics including age at
MMN onset, disease duration, maintenance treatment with
IVIg, muscle strength, presence and titer of serum anti-
GM1 IgM antibodies, or the presence of HLA type HLA-
DRB1*15. Two MMN patients had celiac disease. Serum
of one of these patients contained anti-GM1 IgM anti-
bodies (titer 1:400) but no other anti-ganglioside antibod-
ies. Twenty-two of 438 controls (5%) had one or more of
the listed AID. Four controls (0.9%) had more than one
AID (psoriasis and RA; Graves’ hyperthyroidism and RA;
MG and RA; psoriasis and Hashimoto’s thyroid disease).
Prevalence of AID was higher in MMN patients com-
pared to controls [odds ratio (OR) 2.4, 95% conﬁdence
interval (CI) 1.1–5.5, p = 0.037]. Females were more
affected by AID compared to males: 50% of affected
subjects in MMN patients were females (v
2 p = 0.02) and
41% of affected indices in controls were females (v
2
p = 0.07) while the total percentage of females in both
groups was 25% (Table 1). Celiac disease (two MMN
patients), Crohn’s disease (one patient), ankylosing
Table 1 Characteristics of MMN patients and controls
Patients Controls
Total number of indices 81 438
Number of affected indices
(% of total)
9 (11%) 22 (5%)
Number of females (% of total) 20 (25%) 108 (25%)
Number of females in
affected indices (% of total)
5 (56%) 9 (41%)
Age (years) at inclusion
(median, range)
55 (30–77) 60 (22–90)
Age (years) at inclusion of affected
indices (median, range)
49 (41–67) 54 (46–77)
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123spondylitis (one MMN patient) and cutaneous lupus ery-
thematosus (one MMN patient) were exclusively observed
in MMN patients but not in controls.
AID in case and control families
Table 3 summarizes the prevalence of AID in relatives of
MMN patients and controls. Twenty-eight out of 417
family members of patients with MMN had an AID (6.7%),
whereas 157 out of 2,377 relatives from controls had an
AID (6.6%) (OR 1.0, 95% CI 0.7–1.6; p = 0.93). Type 1
diabetes, Hashimoto’s thyroid disease, and celiac disease
were signiﬁcantly more prevalent in family members of
patients than of controls. To exclude reporting bias,
patients and controls were asked whether they or family
members had asthma or had experienced myocardial
infarction. There was no signiﬁcant difference in preva-
lence of asthma (patients 4.9%, controls 6.4%, p = 0.71;
relatives of patients 2.1%, relatives of controls 2.4%,
p = 0.73) or myocardial infarction (patients 1.2%, controls
4.7%, p = 0.33; relatives of patients 6.5%, relatives of
controls 9.1%, p = 0.08).
Discussion
This study shows that AID may occur more frequently in
patients with MMN compared to controls. This suggests
that patients with MMN may have an increased risk for
AID, and that MMN may share common pathogenic
mechanisms such as genetic background, environmental
triggers and/or changed immune homeostasis with AID
[7, 9].
The main strengths of this study are the relatively large
number of included patients with this rare neuropathy and
the inclusion of relatively large numbers of gender-mat-
ched controls. Baseline characteristics of patients and
controls were comparable except for age at inclusion,
which was signiﬁcantly higher in the control group (med-
ian age 55 versus 60 years). Recall bias or bias introduced
by differences in response rates are unlikely, given the
comparable prevalence of asthma and myocardial infarc-
tion in patients and controls. The prevalence of AID in
controls was within the estimated range (5–9.4%) of the
Dutch Central Bureau for Statistics.
Although the Dutch MMN patient cohort is relatively
large, the main limitation of this study remains its power
[6]. The study is clearly underpowered to detect associa-
tions of speciﬁc AID with MMN due to the rarity of both
MMN and AID. In view of the association with elevated
serum levels of anti-GM1 IgM antibodies, we hypothesized
Table 2 Prevalence of autoimmune diseases in MMN patients and
controls
Disease Prevalence (%)
MMN patients
(n = 81)
Prevalence (%)
controls
(n = 438)
Diabetes type 1 0 0
Graves’ hyperthyroidism 0 0.9
Hashimoto’s thyroid disease 1.2 0.7
Addison’s disease 0 0
Rheumatoid arthritis 0 1.8
Ankylosing spondylitis 1.2 0
Systemic lupus erythematosus 0 0
Cutaneous lupus erythematosus 1.2 0
Sjo ¨gren’s syndrome 0 0
Myasthenia gravis 0 0.2
Multiple sclerosis 0 0
Dermatomyositis 1.2 0
Psoriasis 2.5 1.1
Vitiligo 1.2 0.7
Crohn’s disease 1.2 0
Ulcerative colitis 0 0.2
Celiac disease 2.5 0
Pernicious anaemia 0 0.2
Table 3 Prevalence of autoimmune diseases in relatives of MMN
patients and controls
Disease Prevalence (%)
relatives MMN
patients
(n = 417)
Prevalence (%)
relatives
controls
(n = 2377)
p value
Diabetes type 1 1.2 0.2 0.002
Graves’
hyperthyroidism
0.7 0.8 n.s
Hashimoto’s thyroid
disease
1.4 0.5 0.01
Addison’s disease 0 0 n.s
Rheumatoid arthritis 1.9 1.9 n.s
Ankylosing spondylitis 0.7 0.3 n.s
Systemic lupus
erythematosus
0 0 n.s
Cutaneous lupus
erythematosus
0 0 n.s
Sjo ¨gren’s syndrome 0 0 n.s
Myasthenia gravis 0 0.1 n.s
Multiple sclerosis 0.2 0.4 n.s
Dermatomyositis 0 0.04 n.s
Psoriasis 1.9 1.4 n.s
Vitiligo 0.7 0.2 n.s
Crohn’s disease 0 0.6 n.s
Ulcerative colitis 0 0.3 n.s
Celiac disease 0.2 0 0.02
Pernicious anaemia 0 0.1 n.s
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123that B-cell dysfunction is an important underlying patho-
genic mechanism in MMN. There was no co-segregation of
mainly B-cell-mediated AID such as myasthenia gravis and
systemic lupus erythematosus with MMN. We previously
found that HLA-DRB1*15 is more prevalent among
patients with MMN than in population based controls [15]
similar to patients with MS [13]. However, none of the
MMN patients and only one relative of a MMN patient had
MS. Importantly, the numbers of patients and controls are
too small to draw deﬁnite conclusions or to exclude an
association of B-cell-mediated AID or MS. Although the
use of questionnaires may increase the risk of ascertain-
ment bias, we feel this is unlikely. Telephone interviews
were conducted to conﬁrm the validity of reported diag-
noses. The accuracy of reported diagnoses was also con-
ﬁrmed by the information (correspondence from medical
specialists other than neurologists) available in patient ﬁles.
We also chose to include only ﬁrst-degree relatives to
reduce the risk of including hearsay diagnoses in second-
and third-degree relatives.
Frequencies of diabetes type 1, Hashimoto’s thyroid
disease, and celiac disease were signiﬁcantly increased
among ﬁrst-degree relatives of MMN patients as com-
pared to controls. Celiac disease and Hashimoto’s thy-
roid disease were also more frequent in patients with
MMN than controls. Anti-ganglioside antibodies have
also been reported in patients with celiac disease [2, 3].
One patient with MMN and celiac disease had anti-GM1
IgM antibodies, but the other did not. Although the data
about the autoimmune diseases should be interpreted
with great care due to the small numbers, it is interesting
to note that both type 1 diabetes and celiac disease
[14, 21], and type 1 diabetes and Hashimoto’s thyroid
disease [16, 21] co-segregate. MMN susceptibility may
therefore be determined by genetic variants that are
associated with these clusters, in addition to HLA-
DRB1*15 [15].
The risk of additional AID was highest in female
patients with MMN. This ﬁnding, combined with the pre-
dominance of men with MMN, may suggest gender dif-
ferences in factors that determine susceptibility. Such
differences have been identiﬁed previously in patients with
other inﬂammatory neuropathies [10]. In concordance with
the ﬁndings in control populations, the family histories of
MMN patients show a predominance of women with an
AID. Unlike the ﬁndings in LEMS and MG we found no
speciﬁc maternal transmission pattern of AID in patients
with MMN [8, 20].
Our data suggest that the frequency of additional AID is
increased in patients with MMN. Studies with a larger
sample size to ensure sufﬁcient power are needed to detect
associations with speciﬁc AID that could help to identify
shared risk factors.
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